The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Smoking, The Missing Drug Interaction in Clinical Trials: Ignoring the Obvious
Abstract
Tobacco use is universally recognized as the foremost preventable cause of cancer in the United States and globally and is responsible for 30% of all cancer-related deaths in the United States. Tobacco use, including exposure to secondhand smoke has been implicated as a causal or contributory agent in an ever-expanding list of cancers, including lung, oral cavity and pharynx, pancreas, liver, kidney, ureter, urinary bladder, uterine cervix, and myeloid leukemia. In addition to and independent of the etiologic effects of tobacco carcinogens in numerous cancers, there is a growing literature on the direct and indirect effects of smoking on treatment efficacy (short-term and long-term outcomes), toxicity and morbidity, quality of life (QOL), recurrence, second primary tumors (SPT), and survival time as summarized below. Oncology health professionals have called for increased advocacy for tobacco control. Despite the critical relevance of smoking to cancer outcomes, most oncology clinical trials do not collect data on smoking history and status unless the malignancy is widely acknowledged as smoking related (e.g., lung or head and neck cancer). Usually, these data are collected only at trial registration. Changes in smoking status during treatment or follow-up are monitored in very few trials and are infrequently reported in sample descriptions or included in analysis plans as a potential moderator of outcomes. Based on mounting evidence that tobacco use affects cancer treatment outcomes and survival, we recommend that smoking history and status be systematically collected as core data in all oncology clinical trials: at diagnosis, at trial registration, and throughout treatment and follow-up to long-term survival or death. We feel that the inclusion and analysis of such data in clinical trials will add important information to the interpretation of outcomes and the development of scientific knowledge in this area. Smoking status has been called another “vital sign” because of its relevance to a patient's immediate medical condition. We explain the critical value of knowing the smoking status of every patient with cancer at every visit by providing a brief overview of the following research findings: (a) the effects of tobacco use on cancer treatment and outcome; (b) recent findings on the role of nicotine in malignant processes; (c) some unexpected results concerning tobacco status, treatment, and disease outcome; and (d) identifying key questions that remain to be addressed. We provide a suggested set of items for inclusion in clinical trial data sets that also are useful in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
In search of how people change: Applications to addictive behaviors.
Prochaska, J. O., DiClemente, C. C., & Norcross, J. C. (1992) · American Psychologist · doi:10.1037/0003-066x.47.9.1102 · Cited by 8,596
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404143301501 · Cited by 4,737
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341802 · Cited by 3,638
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire
Fagerstrom, K. O., & Schneider, N. G. (1989) · Journal of Behavioral Medicine · doi:10.1007/bf00846549 · Cited by 1,598
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490 · cited 4×
“Thus, epidermal growth factor receptor-tyrosine kinase inhibitors, alone or combined with chemotherapy, might plausibly specifically benefit never smokers who express epidermal growth factor receptor mutations; this hypothesis awaits testing in a prospective trial (66, 72).”
BackgroundMethodInfluentialOmenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1550 · Cited by 1,255
Stigma, shame, and blame experienced by patients with lung cancer: qualitative study
Chapple, A., Ziebland, S., & McPherson, A. (2004) · BMJ · doi:10.1136/bmj.38111.639734.7c · Cited by 789
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer
Browman, G. P., Wong, G., Hodson, I., Sathya, J., Russell, R., McAlpine, L., Skingley, P., & Levine, M. N. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280302 · Cited by 600 · cited 4×
“(b) The conflicting data in several studies showing no effect versus a positive effect of cessation on prognosis may reflect a lack of adequate data (18, 19, 21, 27, 73); and (c) The effects of smoking on treatment outcomes in nonsmoking-related tumors are unexplored.”
BackgroundMethodInfluential
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Gillison, M. L., Zhang, Q., Jordan, R., Xiao, W., Westra, W. H., Trotti, A., Spencer, S., Harris, J., Chung, C. H., & Ang, K. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4099 · Cited by 487
Gatta, G., Botta, L., Sánchez, M. J., Anderson, L. A., Pierannunzio, D., Licitra, L., Hackl, M., Zielonke, N., Oberaigner, W., Van Eycken, E., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.043 · Cited by 485
Successes and failures of the teachable moment: Smoking cessation in cancer patients
Gritz, E. R., Fingeret, M. C., Vidrine, D. J., Lazev, A. B., Mehta, N. V., & Reece, G. P. (2006) · Cancer · doi:10.1002/cncr.21598 · Cited by 360
Self-citation
Metadata
- Authors
- Gritz, E. R., Dresler, C., & Sarna, L.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2005-10-01
- Volume
- 14
- Issue
- 10
- Pages
- 2287-2293
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2107988875
- Cited by
- 193
- References
- 11
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Smoking, The Missing Drug Interaction in Clinical Trials: Ignoring the Obvious. https://app.cochat.ai/papers/10.1158/1055-9965.epi-05-0224
- The paper
- Gritz, E. R., Dresler, C., & Sarna, L. (2005). Smoking, The Missing Drug Interaction in Clinical Trials: Ignoring the Obvious. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-05-0224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.